Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 1:15:e00036.
doi: 10.1016/j.fawpar.2019.e00036. eCollection 2019 Jun.

Treatment of toxoplasmosis: Current options and future perspectives

Neda Konstantinovic  1 , Hélène Guegan  2 , Tijana Stäjner  1 , Sorya Belaz  2 , Florence Robert-Gangneux  2
Affiliations
Review

Treatment of toxoplasmosis: Current options and future perspectives

Neda Konstantinovic et al. Food Waterborne Parasitol. .

Erratum in

Abstract

Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years. This article aims at reviewing the main clinical trials and current treatment practices, and at addressing future perspectives in the light of ongoing researches.

PubMed Disclaimer

References

    1. Adeyemi O.S. Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents. Parasitol. Res. 2018;117(2):355–363. - PubMed
    1. Adriaensen W. Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients. Front. Immunol. 2018;8 - PMC - PubMed
    1. Afifi M.A., Al-Rabia M.W. The immunomodulatory effects of rolipram abolish drug-resistant latent phase of Toxoplasma gondii infection in a murine model. J. Microsc. Ultrastruct. 2015;3(2):86–91. - PMC - PubMed
    1. Alday P.H., Doggett J.S. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des. Devel. Ther. 2017;11:273–293. - PMC - PubMed
    1. Arens J. Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids. S. Afr. Med. J. 2007;97(10):956–958. - PubMed

LinkOut - more resources